Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in
December 2019 and causes coronavirus (CoV) disease 2019 (COVID-19). The virus …
December 2019 and causes coronavirus (CoV) disease 2019 (COVID-19). The virus …
Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries
Y Pan, J Du, J Liu, H Wu, F Gui, N Zhang, X Deng… - Cell Discovery, 2021 - nature.com
As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to
threaten public health worldwide, the development of effective interventions is urgently …
threaten public health worldwide, the development of effective interventions is urgently …
Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
COVID-19 has caused a global pandemic and millions of deaths. It is imperative to develop
effective countermeasures against the causative viral agent, SARS-CoV-2 and its many …
effective countermeasures against the causative viral agent, SARS-CoV-2 and its many …
Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models
Nanobodies offer several potential advantages over mAbs for the control of SARS-CoV-2.
Their ability to access cryptic epitopes conserved across SARS-CoV-2 variants of concern …
Their ability to access cryptic epitopes conserved across SARS-CoV-2 variants of concern …
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
SARS-CoV-2 variants with adaptive mutations have continued to emerge, causing fresh
waves of infection even amongst vaccinated population. The development of broad …
waves of infection even amongst vaccinated population. The development of broad …
The potential of nanobodies for COVID-19 diagnostics and therapeutics
DB Naidoo, AA Chuturgoon - Molecular Diagnosis & Therapy, 2023 - Springer
The infectious severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the
causative agent for coronavirus disease 2019 (COVID-19). Globally, there have been …
causative agent for coronavirus disease 2019 (COVID-19). Globally, there have been …
Engineered multivalent nanobodies potently and broadly neutralize SARS‐CoV‐2 variants
JM Zupancic, JS Schardt, AA Desai… - Advanced …, 2021 - Wiley Online Library
The COVID‐19 pandemic continues to be a severe threat to human health, especially due to
current and emerging SARS‐CoV‐2 variants with potential to escape humoral immunity …
current and emerging SARS‐CoV‐2 variants with potential to escape humoral immunity …
A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2
H Yao, H Cai, T Li, B Zhou, W Qin, D Lavillette… - PLoS …, 2021 - journals.plos.org
A key step to the SARS-CoV-2 infection is the attachment of its Spike receptor-binding
domain (S RBD) to the host receptor ACE2. Considerable research has been devoted to the …
domain (S RBD) to the host receptor ACE2. Considerable research has been devoted to the …
Therapeutic role of neutralizing antibody for the treatment against SARS-CoV-2 and its emerging variants: A clinical and pre-clinical perspective
Since early 2020, the entire world has been facing a disastrous outbreak of the SARS-CoV-2
virus, with massive reporting of death and infections per day. Medical practitioners adopted …
virus, with massive reporting of death and infections per day. Medical practitioners adopted …
Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: Current update
M Bhattacharya, S Chatterjee, SS Lee… - International Journal of …, 2023 - Elsevier
In the last two years, the world encountered the SARS-CoV-2 virus, which is still dominating
the population due to the absence of a viable treatment. To eradicate the global pandemic …
the population due to the absence of a viable treatment. To eradicate the global pandemic …